Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Horby

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
The Lancet. Infectious Diseases|December 24, 2021
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendationsHerman Goossens, Lennie Derde, Peter Horby, et al.
The New England Journal of Medicine|February 10, 2021
Hydroxychloroquine in Hospitalized Patients with Covid-19. ReplyPeter Horby, Nicholas J White, Martin J Landray
Clinical Trials (London, England)|January 16, 2016
Trial design for evaluating novel treatments during an outbreak of an infectious diseaseJohn Whitehead, Piero Olliaro, Trudie Lang, et al.
Lancet (London, England)|July 25, 2021
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' replyPeter Horby, Natalie Staplin, Richard Haynes, et al.
Medical Education|April 14, 2016
Teaching research methodology within an Ebola virus outbreakBen Hope-Gill, Baimba Idriss, Thomas Massaquoi, et al.
The Lancet Regional Health. Southeast Asia|January 27, 2025
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'Md Zakiul Hassan, Amanda Rojek, Piero Olliaro, et al.
Lancet (London, England)|May 8, 2022
Allocated but not treated: the silent 16% - Authors' replyPeter Horby, Natalie Staplin, Jonathan Emberson, et al.
The Lancet. Global Health|December 18, 2018
Clinical research networks and assessing pandemic severitySrinivas Murthy, Gail Carson, Peter Horby, et al.
The Lancet. Infectious Diseases|January 23, 2023
Randomised controlled trials for mpox in endemic countriesAmanda Rojek, Jake Dunning, Richard Haynes, et al.
Plos One|September 12, 2018
Performance of different clinical trial designs to evaluate treatments during an epidemicMatthias Brueckner, Andrew Titman, Thomas Jaki, et al.
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
The Lancet. Infectious Diseases|December 24, 2021
The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendationsHerman Goossens, Lennie Derde, Peter Horby, et al.
The New England Journal of Medicine|February 10, 2021
Hydroxychloroquine in Hospitalized Patients with Covid-19. ReplyPeter Horby, Nicholas J White, Martin J Landray
Clinical Trials (London, England)|January 16, 2016
Trial design for evaluating novel treatments during an outbreak of an infectious diseaseJohn Whitehead, Piero Olliaro, Trudie Lang, et al.
Lancet (London, England)|July 25, 2021
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' replyPeter Horby, Natalie Staplin, Richard Haynes, et al.
Medical Education|April 14, 2016
Teaching research methodology within an Ebola virus outbreakBen Hope-Gill, Baimba Idriss, Thomas Massaquoi, et al.
The Lancet Regional Health. Southeast Asia|January 27, 2025
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'Md Zakiul Hassan, Amanda Rojek, Piero Olliaro, et al.
Lancet (London, England)|May 8, 2022
Allocated but not treated: the silent 16% - Authors' replyPeter Horby, Natalie Staplin, Jonathan Emberson, et al.
The Lancet. Global Health|December 18, 2018
Clinical research networks and assessing pandemic severitySrinivas Murthy, Gail Carson, Peter Horby, et al.
The Lancet. Infectious Diseases|January 23, 2023
Randomised controlled trials for mpox in endemic countriesAmanda Rojek, Jake Dunning, Richard Haynes, et al.
Plos One|September 12, 2018
Performance of different clinical trial designs to evaluate treatments during an epidemicMatthias Brueckner, Andrew Titman, Thomas Jaki, et al.
Pageof 19